Results 51 to 60 of about 15,937 (243)
Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy [PDF]
, 2009 The present review aims to examine the effect of specific drugs on long-term outcome of pulmonary arterial hypertension (PAH), to critically review the available data, and to derive useful information for daily patient care.
Delcroix, Marion +2 more
core +2 more sources
Novel pathways of heart failure with preserved ejection fraction [PDF]
, 1875 INTRODUCTION: Diastolic heart failure (HF) i.e., HF with preserved ejection fraction (HFpEF) accounts for ~50% of all clinical HF presentations; but unlike systolic HF i.e., HF with reduced ejection fraction (HFrEF), there are no evidenced based ...
Li, Shanpeng
core +2 more sources
Molecular Cancer, 2010 Background The endothelin system is implicated in the pathogenesis of melanoma. We evaluated the effects of bosentan - a dual endothelin receptor antagonist - in patients receiving first-line dacarbazine therapy for stage IV metastatic cutaneous melanoma
Ballmer Andrea +5 more
doaj +1 more source
Chronic dosing with metformin plus bosentan decreases in vitro pulmonary artery contraction from isolated arteries in adults with pulmonary hypertension [PDF]
Journal of Cardiovascular and Thoracic Research, 2019 Introduction: Pulmonary arterial hypertension (PAH) specific drug therapy using bosentan has significantly improved quality of life and survival, although PAH is still an incurable disease.
Shutan Liao +4 more
doaj +1 more source
Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan [PDF]
, 2019 Objectives: To assess whether switching patients with suboptimally controlled pulmonary arterial hypertension from bosentan or ambrisentan to macitentan would improve six-minute walk test (6MWT) distance and World Health Organization functional class ...
Gabbay, Eli +3 more
core +1 more source
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.Summary Background and objectives Systemic sclerosis (SSc) is a rare, chronic autoimmune disease characterized by fibrosis of the skin and/or internal organs. Emerging evidence suggests that subcutaneous adipose tissue may contribute to systemic inflammation and fibrosis in SSc.
Marija Geroldinger‐Simić +3 more
wiley +1 more source
Drug Delivery, 2017 Bosentan is an endothelin receptor antagonist (ERA) prescribed for patients with pulmonary arterial hypertension (PAH). The oral delivery of bosentan possesses several drawbacks such as low bioavailability (about 50%), short duration of action, frequent ...
Lydia A. Hanna +2 more
doaj +1 more source
The role of the right ventricle in pulmonary arterial hypertension [PDF]
, 2011 Although changes in the pulmonary vasculature are the primary cause of pulmonary arterial hypertension (PAH), severity of symptoms and survival are strongly associated with right ventricular function, and right heart failure is the main cause of death in
Galie, N., Vonk Noordegraaf, A.
core +2 more sources
The Use of Treprostinil for Bronchopulmonary Dysplasia Associated Pulmonary Hypertension
Pediatric Pulmonology, Volume 61, Issue 1, January 2026.ABSTRACT Background Treprostinil for the treatment of bronchopulmonary dysplasia‐associated pulmonary hypertension (BPD‐PH) has previously been described in small cohort studies, often used later in the course after failure to improve on other therapies.
Stephanie M. Tsoi +8 more
wiley +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016 BackgroundEvidence of the clinical safety of endothelin receptor antagonists (ERAs) is limited and derived mainly from individual trials; therefore, we conducted a meta‐analysis.
Anhua Wei +6 more
doaj +1 more source